Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01756352 · ClinicalTrials.gov registry record · Phase 2
FET-PET for Evaluation of Response of Recurrent GBM to Avastin
A Phase 2 study, sponsored by Marcelo F. Di Carli, MD, FACC.
- Completed
- Registry status
- Phase 2
- Development phase
- 13
- Enrollment target
NCT01756352: Completed Phase 2 study, sponsored by Marcelo F. Di Carli, MD, FACC.
NCT01756352 is a Phase 2 study that has completed, run by Marcelo F. Di Carli, MD, FACC. The registered enrollment target is 13 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (90% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01756352, a Phase 2 study, has completed, sponsored by Marcelo F. Di Carli, MD, FACC.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 13 participants
- Enrollment target
Study Summary
Hypothesis: The central hypothesis underlying the proposed research study is that FET-PET will predict durable benefit in patients receiving anti-angiogenic benefit for presumed recurrent GBM (i.e. progression-free survival and overall survival). We have defined one primary specific aim, for which we expect to obtain definitive results, and two secondary aims, under which we plan to generate preliminary data to support a future, larger project.
Primary Outcome
The primary objective is to assess the utility of FET-PET imaging for prediction of progression-free survival in recurrent glioblastoma.
Interventions
- DRUG 18F-FET
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2013-02 |
| Est. Completion | 2015-09-13 |
| Phase | Phase 2 |
What the finished NCT01756352 record still lists
NCT01756352 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 13 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (90% lower).
The record links to 0 conditions, and to 1 intervention - of which 18F-FET is the first listed.
NCT01756352 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01756352 about?
NCT01756352 is a clinical study titled "FET-PET for Evaluation of Response of Recurrent GBM to Avastin". Hypothesis: The central hypothesis underlying the proposed research study is that FET-PET will predict durable benefit in patients receiving anti-angiogenic benefit for presumed recurrent GBM (i.e. progression-free survival and overall survival). We have defined one primary specific aim, for which w...
What is the current status of trial NCT01756352?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 13 participants. The study started on 2013-02. Estimated completion is 2015-09-13.
What interventions are being tested in trial NCT01756352?
The interventions under investigation include: 18F-FET (DRUG).
Who is sponsoring clinical trial NCT01756352?
This trial is sponsored by Marcelo F. Di Carli, MD, FACC, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01756352's enrollment target sits among peer trials
13 1947th of 2000 higher than 53 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03125655 · 13 participants
Regulation of Inflammatory Genes in Psoriasis
- NCT03774446 · 13 participants · Phase 2
Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease
- NCT03830151 · 13 participants · Phase 1
Hyperpolarized Carbon C 13 Pyruvate in Diagnosing Glioma in Patients With Brain Tumors
- NCT04573231 · 13 participants · Phase 2
Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia